Said Darwazah, Chairman and CEO of Hikma said, “This is our first launch from the Bedford portfolio acquired last year. We are making good progress in the transfer of the Bedford products to our manufacturing facilities and this launch demonstrates our strong R&D, regulatory and manufacturing capabilities."
According to IMS Health, sales of caffeine citrate injection in the US market were approximately $7.6 million for the 12 months ending March 2015.